FLAVOXATE TREATMENT OF MICTURITION DISORDERS ACCOMPANYING BENIGN PROSTATIC HYPERTROPHY - A DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER INVESTIGATION

被引：25

作者：

DAHM, TL ^{[1
]}

OSTRI, P ^{[1
]}

WALTER, S ^{[1
]}

FRIMODTMOLLER, C ^{[1
]}

RASMUSSEN, RB ^{[1
]}

NOHR, M ^{[1
]}

ALEXANDER, N ^{[1
]}

机构：

[1] GENTOFTE UNIV HOSP,DEPT UROL,GENTOFTE,DENMARK

来源：

UROLOGIA INTERNATIONALIS | 1995年 / 55卷 / 04期

关键词：

BENIGN PROSTATIC HYPERTROPHY; MEDICAL TREATMENT; FLAVOXATE;

D O I：

10.1159/000282787

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

To investigate the effect of flavoxate (Urispadol(R)) treatment on patients with symptomatic benign prostatic hypertrophy (BPH), with the main weight on the irritative symptoms, a randomized, double-blind, parallel-group, placebo-controlled and multicenter investigation was carried out. Seventy patients entered the study, 37 were allocated to flavoxate treatment on a daily dose of 1,200 mg (400 mg t.i.d.) for 12 weeks, and 33 patients were allocated to placebo treatment. In spite of a sufficient power, the study did not discriminate the two treatment groups in a statistically significant way (p > 0.05), when considering the main endpoints: the irritative symptom score and the global patient evaluation. Conservative treatment of micturition disorders accompanying BPH with flavoxate in doses of 1,200 mg/day cannot be recommended for clinical use.

引用

页码：205 / 208

页数：4

共 11 条

[1]

Barry M.J., Epidemiology and natural history of benign prostatic hyperplasia, Urol Clin North Am, 17, pp. 495-506, (1990)

[2]

Speakman M.J., Scthia K.K., Fellows C.J., Smith J.C., A study of the pathogenesis, urodynamic assessment and outcome of detrusor instabilityassociated with bladder outflow obstruction, Br J Urol, 59, pp. 40-44, (1987)

[3]

Ruffmann R., A review of flavoxate hydrochloride in the treatment of urge incontinence, J Int Med Res, 16, pp. 317-330, (1988)

[4]

Conti M., Setnikar I., Flavoxate, a potent phosphodiesterase inhibitor, Arch Int Pharmacodvn Ther, 213, pp. 186-189, (1975)

[5]

Cazzulani P., Panzarasa R., Luca C., Oliva D., Graziani G., Pharmacological studies on the mode of action of flavoxate, Arch Int Pharmacodyn Ther, 268, pp. 301-312, (1984)

[6]

Abbiati G.A., Cesarani R., Nardi D., Pictra C., Testa R., Receptor binding studies of the flavone, REC 15/2053, and other bladder spasmolytics, Pharmacol Res, 5, pp. 430-433, (1988)

[7]

Ruffmann R., Sartini A., Flavoxate, a drug with smooth muscle relaxing activity, Int J Drugs Exp Clin Res, 13, pp. 57-62, (1987)

[8]

Cucchi A., Colli E., Bladder voiding dynamics in BPH patients treated with high dose flavoxate, Proc 20th Congr Int Continence Society, pp. 215-216, (1990)

[9]

Jensen K.M.E., Jorgensen J.B., Mogcnsen P., Billc-Brahc N.E., Some clinical aspects of uroflowmetry in elderly males, Scand J Urol Nephrol, 20, pp. 93-99, (1986)

[10]

Ostri P., Swartz R., Meyhoff H.H., Petersen J.H., Lindgaard G., Frimodt-Moller C., Andersson T., Nielsen M.S., Antiandrogenic treatment of benign prostatic hyperplasia: A placebo controlled trial, Urol Res, 17, pp. 29-33, (1989)

← 1 2 →